We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01255982
First Posted: December 8, 2010
Last Update Posted: October 26, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
This study aims to study prospectively for 8 months a sample of bipolar patients with acute depressive episode in order to identify that factors associated with functional impairment, with especial attention to the presence of subsyndromal symptoms beyond the acute phase.

Condition
Bipolar Disorder Bipolar Depression

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Difference between basal and final Functional Assessment Staging (FAST) score to evaluate the functional change [ Time Frame: Range of Days 0-3 ]

Secondary Outcome Measures:
  • FAST score to estimate the proportion of patients that not achieve functional remission [ Time Frame: Range of Days 0-3 ]
  • Test Screen for Cognitive Impairment in Psychiatry (SCIP) to evaluate cognitive impairment both in the depressive phase and during clinical remission [ Time Frame: Range of Days 0-3 ]
  • Mood chart (self-report) [ Time Frame: Range of Days 0-3 ]
  • The presence of subsyndromal symptoms after the acute depressive phase using Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Diagnostic and Statistical Manual of Mental disorders (DSM-IV-TR) [ Time Frame: Range of Days 0-3 ]

Enrollment: 249
Study Start Date: March 2011
Study Completion Date: October 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Outpatients from Mental Health Centres or Psychiatric Offices, diagnosed with bipolar I or II disorder experiencing an acute depressive episode.
Criteria

Inclusion Criteria:

  • Diagnosis of Bipolar Disorder I or II (DSM-IV-TR)
  • Acute depressive episode at inclusion

Exclusion Criteria:

  • Inability (in investigator´s opinion) to carry out the follow-up plan
  • Patients participating or having participated within previous 6 months, in clinical trials
  • Mental retardation or any other medical condition affecting cognitive performance
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01255982


Locations
Spain
Research Site
Elche, Alicante, Spain
Research Site
Villajoyosa, Alicante, Spain
Research Site
Sama de Langreo, Asturias, Spain
Research Site
Granollers, Barcelona, Spain
Research Site
San Boit de LLobregat, Barcelona, Spain
Research Site
Monforte de Lemos, Lugo, Spain
Research Site
Tudela, Navarra, Spain
Research Site
Mos, Pontevedra, Spain
Research Site
Catarroja, Valencia, Spain
Research Site
Almería, Spain
Research Site
Barcelona, Spain
Research Site
Cordoba, Spain
Research Site
Granada, Spain
Research Site
Lerida, Spain
Research Site
Madrid, Spain
Research Site
Malaga, Spain
Research Site
Orense, Spain
Research Site
Palencia, Spain
Research Site
Palma de Mallorca, Spain
Research Site
Sevilla, Spain
Research Site
Tarragona, Spain
Research Site
Valencia, Spain
Research Site
Zamora, Spain
Research Site
Zaragoza, Spain
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01255982     History of Changes
Other Study ID Numbers: NIS-NES-DUM-2010/1
First Submitted: December 7, 2010
First Posted: December 8, 2010
Last Update Posted: October 26, 2012
Last Verified: October 2012

Keywords provided by AstraZeneca:
Bipolar depression
subsyndromal symptoms
functioning
cognitive function

Additional relevant MeSH terms:
Depression
Depressive Disorder
Bipolar Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Bipolar and Related Disorders